



# UCLA BIOMEDICAL & LIFE SCIENCE INNOVATION DAY 2018

Advancing Science, Fostering Partnerships

# O2

## CONTENTS

Welcome Message	O3
Conference Schedule	O4
Speaker Profiles	O6
Pearl Cohen Poster Award Description	16
Conference Sponsors and Partners	18
Amgen Early Innovator Award Description	21
Contact Information	24

## Welcome



**Welcome to the UCLA Biomedical & Life Science Innovation Day**, organized by the UCLA Technology Development Group, at the Meyer and Renee Luskin Conference Center on the campus of the University of California, Los Angeles.

Today's event is intended to promote awareness of the growing life science entrepreneurial ecosystem at UCLA and to foster partnerships with pharmaceutical, biotechnology and life science industries. The focus is to showcase leading UCLA life science translational research programs and start-ups where UCLA has significant expertise, pioneering research and resources directed towards developing innovative solutions for important unmet medical needs.

By joining us for this event you will have the opportunity to listen to engaging panel discussions, participate in networking and breakout meetings and view posters by UCLA faculty, postdoctoral fellows and graduate students.

Thank you to our sponsors for making today a possibility and thank you to each of you for attending the UCLA Biomedical & Life Science Innovation Day.

We hope you find today's program inspiring, educational and enjoyable.

# Schedule

O5

7:30AM	8:30AM	8:35AM	8:45AM	8:55AM	9:15AM	9:45AM	10:00AM
Registration: Continental Breakfast	UCLA Technology Development Group Introduction Address  Amir Naiberg, Associate Vice Chancellor, UCLA Technology Development Group, CEO & President, UCLA Technology Development Corporation.	UCLA Welcome Address  Kelsey Martin, UCLA Dean, David Geffen School of Medicine.	Opening Remarks  David A. Piacquad, Senior Vice President, Business Development, Amgen.	Industry — Academic Collaborations  Michael Jung, UCLA Distinguished Professor, An inventor of prostate cancer drugs Xtandi® and Erleada™.	Kite, A Gilead Company: Research Capabilities & Priorities  Peter Emtage, Senior Vice President, Head of Cell Therapy Research, Kite, A Gilead Company.	Morning Break & Poster Viewing	Welcome  John C. Mazziotta, Vice Chancellor, UCLA Health Sciences, CEO, UCLA Health.
10:05AM	10:15AM	12:00PM		12:00PM	1:15PM		2:00PM
Los Angeles County Bioscience Initiative  Mark Ridley-Thomas, Supervisor 2nd District, Los Angeles County.	UCLA Unified Research Themes: Cardiovascular   Metabolism   Cancer   Neuroscience   Institute For Precision Health   I3T   Regenerative Medicine  Tom Carmichael Lawrence Zipursky Yibin Wang Daniel H. Geschwind Michael A. Teitell Steven Bensinger Orian Shirihai	Lunch		Academia — Industry Career Transition Panel  Agi Hamburger, Senior Director Drug Discovery, A2 Biotherapeutics. Dustin Khiem, Senior Director of Medical Communications, Kite, A Gilead Company. Arianne Perez, Principal Scientist, Kite, A Gilead Company. Tracy Mitchell Blois, Director Alliance Management, Business Development, Amgen.	University Technology to Company Panel  Isaac Ciechanover, CEO & President, Atara Bio. Bassil Dahiyat, CEO, Xencor. John Hood, Founder & CEO, Impact Biomedicines. James Treanor, President & CEO, ADRx.		Amgen Research Capabilities & Interests  Raymond Deshaies, Senior Vice President, Discovery Research, Amgen. David Reese, Senior Vice President, Translational Science & Oncology, Amgen.
2:30PM	3:00PM	3:45PM		4:00PM	4:45PM		5:00PM
Afternoon Break & Poster Viewing	Meet Leaders In The Business Of Life Sciences: Scientific Innovation, Drug Development And Financing — Start Ups & Growth Companies Panel  Jagdeep Singh Bachher, Chief Investment Officer, University of California, Office of the President. Arie Belldegrun, Director of Institute of Urologic Oncology, UCLA Health, Founder, Kite Pharma, Inc. David Chang, CEO, Allogene Therapeutics. John DeYoung, Vice President Worldwide Business Development, Pfizer. John Milligan, President and CEO, Gilead Sciences. Rajiv Kaul, Portfolio Manager, Fidelity Investments.	Afternoon Break & Poster Viewing		Evaluation Of University Technologies: Success Drivers & Pitfalls Panel  Dan Estes, Partner, Frazier Healthcare Partners. Vijay Murthy, Principal, Johnson & Johnson Innovation, JJDC, Inc. Janis Naeve, Executive Director, Amgen Ventures. Barbara Sosnowski, Vice President & Global Head — External R&D Innovation, Pfizer. Douglas Crawford, Managing Director, Mission Bay Capital, General Manager, MBC Biolabs. Karim Helmy, Vice President, Venrock.	Amgen Early Innovator Award Announcement  David A. Piacquad, Senior Vice President, Business Development, Amgen.		Reception: Hors D’oeuvres & Beverages



# Speakers

07



**JAGDEEP S. BACHHER**  
(Chief Investment Officer, Office of the Chief Investment Officer of the Regents University of California, Office

of the President) is responsible for managing \$118 billion across the UC Endowment, Pension, Retirement Savings, Working Capital and Insurance on behalf of the Board of Regents of the University of California. Before joining the UC in March 2014, Bachher held the roles of Deputy Chief Investment Officer and Chief Operating Officer at Alberta Investment Management Corp. (AIMCo) in Alberta, Canada. From 2004 to 2009, Bachher worked in the U.S. Wealth Management, Canadian, and Investments divisions of Manulife Financial. Bachher is chairman emeritus of the Institutional Investors Roundtable and received his Ph.D. and M.A.Sc. degrees in management sciences and B.A.Sc. degree in mechanical engineering from University of Waterloo, Canada.



**ARIE BELLDEGRUN**  
(Director, Institute of Urologic Oncology; Executive Chairman; Senior Managing Director.

David Geffen School Of Medicine at UCLA, Allogene Therapeutics; Vida Ventures) has a distinguished career as a visionary surgeon, scientist and life sciences entrepreneur. He co-founded and serves as Executive Chairman of Allogene Therapeutics, a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic CAR T therapy. Arie founded Kite Pharma, the cell therapy company that developed the first FDA approved autologous CAR T therapy for non-Hodgkin lymphoma. He served as Chairman, President and CEO of Kite until its acquisition by Gilead

Sciences in 2017. Arie has been involved with the founding and advancement of several successful companies including Cougar Biotechnology and Agensys. He is Co-Founder and Senior Managing Director of Vida Ventures and Chairman of Two River Group and UroGen Pharma. Arie is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine.



**STEVEN BENSINGER**  
(Associate Professor, Departments of Microbiology, Immunology, and Molecular Genetics &

Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine) is an Associate Professor of Microbiology, Immunology, and Molecular Genetics, and of Molecular and Medical Pharmacology. He received his Veterinary Medical Degree and Doctor of Philosophy in Immunology from the University of Pennsylvania. Dr. Bensinger's thesis work was completed under the mentorship of Dr. Laurence Turka, and focused on the development and function of CD4 regulatory T cells. Dr. Bensinger subsequently completed a postdoctoral fellowship in the laboratory of Dr. Peter Tontonoz at UCLA, where he examined the impact of lipid metabolism on lymphocyte function and adaptive immunity. Since establishing his own laboratory at UCLA, Dr. Bensinger has emerged as a leader in understanding the influence of lipid metabolism on the immune system. Dr. Bensinger currently serves as Director of Immunology, Inflammation, Infection and Transplantation (I3T) Research at UCLA David Geffen School of Medicine.



**TRACY MITCHELL BLOIS**  
(Director Alliance Management, Business Development, Amgen) has spent more than a decade working in

biotechnology and presently works as a director in Alliance Management with Amgen's Business Development group. In this role, she is accountable for a diverse set of early and late stage partnerships across Amgen's portfolio. Previously, as the head of Business Development's Operations group, she led a team to support the successful identification, evaluation, and execution of licensing and equity collaborations across the company. Before joining Amgen, Tracy was a Principal Scientist at Grifols, Inc. developing and validating QC methods. Earlier in her career, she worked as a marketing intern with UCLA's Office of Intellectual Property. Tracy is an active member of the STEM outreach community, serving as a mentor with Amgen's mentoring program and as a past president of the local Association for Women in Science (AWIS) chapter. Tracy earned a Ph.D. in Biochemistry and Molecular Biology from UCLA studying membrane protein folding under the Chemistry-Biology Interface Training Fellowship and a BA in Biochemistry from the University of San Diego.



**S. THOMAS CARMICHAEL** (Professor & Frances Stark Endowed Chair, Department of Neurology; Co-Director, Broad Stem Cell Research Center) is a neurologist and neuroscientist in the Departments of Neurology and of Neurobiology at the David Geffen School of Medicine at UCLA. Dr. Carmichael is Professor and Chair of the Department of Neurology, co-Director of the UCLA Broad Stem Cell Center and co-Director of the Regenerative Medicine Theme in the David Geffen School of Medicine. He has active

laboratory and clinical interests in stroke and neurorehabilitation and how the brain repairs from injury. He received his M.D. and Ph.D. degrees from Washington University School of Medicine in 1993 and 1994, and completed a Neurology residency at Washington University School of Medicine, serving as Chief Resident. Dr. Carmichael was a Howard Hughes Medical Institute postdoctoral fellow at UCLA from 1998-2001. Dr. Carmichael's laboratory studies the molecular and cellular mechanisms of neural repair after stroke and other forms of brain injury. Dr. Carmichael is an attending physician on the General Neurology & Neurorehabilitation clinical services at UCLA.



**DAVID D. CHANG**  
(President & Chief Executive Officer, Allogene Therapeutics) is the President, CEO and Co-Founder of

Allogene Therapeutics, a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic CAR T therapy. David previously served as EVP, Research & Development, and Chief Medical Officer of Kite, a Gilead Company. He has an industry-leading track record of innovation in the field of oncology drug development, including the development of Yescarta™, the first CAR T therapy approved for non-Hodgkin lymphoma. He held leadership roles at Amgen and spearheaded development strategies that led to the approvals of Vectibix®, Blincyto® and IMLYGIC™. David previously held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at UCLA. He is a Venture Partner at Vida Ventures and serves as a Director at A2 Biotherapeutics and Peloton Biotherapeutics, and a scientific advisory board member for Kronos Bio.



**ISAAC CIECHANOVER**  
(President & Chief Executive Officer, Atara Biotherapeutics) is a physician, investor and entrepreneur driven by

a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in August 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene's Executive Director for Business Development, he spearheaded the company's venture capital efforts and led licensing and M&A activities with an aggregate value of more than \$6.7 billion. Also at Celgene, he was Global Project Leader for the company's first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequot Ventures' healthcare practice and Pfizer. Intellectually curious (and undeterred by student debt), Isaac holds a B.A. from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an M.B.A. from Harvard Business School. For fun, he enjoys cycling, scuba diving and building Lego with his two children. His all-time favorite albums are Pink Floyd's "The Dark Side of the Moon," Radiohead's "OK Computer" and Ruggero Leoncavallo's Italian opera, Pagliacci, with Herbert Von Karajan conducting.



**MARK COHEN** (Senior Partner & Chair, Life Sciences Practice Group, Pearl Cohen) is a Founder, Senior Partner and Chair of the Life Science Practice

Group at Pearl Cohen Zedek Latzer Baratz, LLP. Pearl Cohen has offices in New York, Boston, London and Israel. He is admitted to the New York and New Jersey bars. He is a registered patent attorney experienced in patent prosecution in the pharmaceutical, chemical, biological and medical device area; licensing, commercial matters; and client counseling. He is well versed in various aspects of patent prosecution, intellectual property management, strategic advise, technology assessment, and licensing matters, including management of large patent portfolios, negotiating terms and drafting agreements, and counseling start-ups. He has been involved in large due diligence matters; infringement, validity, and patentability opinions; European patent opposition proceedings; reexamination proceedings; and enforcement matters. His clients that he represents range from start-up companies to Fortune 500 companies.



**DOUGLAS CRAWFORD**  
(Managing Director, Mission Bay Capital; General Manager, MBC BioLabs) Douglas Crawford's goal is to

help entrepreneurial scientists create successful startups. To this end, Doug and his colleagues have systematically lowered the barriers between great ideas and successful companies. For instance, Doug created and manages MBC BioLabs. This state-of-the-art co-working laboratory program in San Francisco allows entrepreneurs to rapidly generate data without getting bogged down in facility management. Doug also founded and manages the early-stage venture fund Mission Bay Capital, which has now invested in 40 companies (21 of which have been UC spin-outs) and has already had 6 exits. Together, Mission Bay Capital and MBC BioLabs empower

entrepreneurs to create awesome companies.



**BASSIL DAHIYAT** (*President & Chief Executive Officer, Xencor*) has been Xencor's president and chief executive officer

since the Company's incorporation in August 1997, and is the co-founder of Xencor, and co-inventor of Xencor's breakthrough XmAb® technology. He has led the Company in raising over \$700 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases, and establishing alliances with leading biopharmaceutical companies that generated over \$200 million in upfront payments. Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 US and numerous foreign patents, and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech.



**RAYMOND DESHAIES** (*Senior Vice President, Discovery Research, Amgen*) is senior vice president, Discovery Research. Prior to joining

Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech's Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute. In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded

Cleave Biosciences. Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the National Academy of Sciences.



**JOHN DeYOUNG** (*Vice President, Worldwide Business Development, Pfizer*) is Vice President of Worldwide Business Development for Pfizer's

Oncology Business Unit. In addition to leading oncology business development, John also has corporate business development responsibilities. John leads a team that provides search and evaluation and transaction support for oncology. John joined Pfizer in 1991 in U.S. Pharmaceutical Finance. After three years in Finance, John joined the U.S. Marketing organization supporting Norvasc, Procardia XL, and New Product Development (NPD). In 1997, John became the U.S. Team Leader of NPD and in 2000 his role was expanded to NPD Group Leader of Worldwide Pharmaceuticals. In 2006, John joined Worldwide Business Development. He is a member of the Oncology Leadership Team and Worldwide Business Development Leadership Team. John received a bachelor's degree in Business from Michigan State University in 1985 and an MBA from the University of Chicago in 1990.



**PETER EMTAGE** (*Senior Vice President, Head of Cell Therapy Research, Kite, A Gilead Company*) serves as the Global Head of Cell Therapy

Research. Peter most recently served as the Chief Scientific Officer at Cell Design Labs. He previously held senior positions at Intrexon, MedImmune and Femta Pharmaceuticals. Peter is an

immunologist by training and over the past 20 years has focused on developing drugs to modulate the immune response in humans. His work in oncology, autoimmunity and infectious disease has included the utilization of viral and non-viral delivery systems, chimeric antigen receptors and TCR adoptive T cell modalities, and monoclonal antibodies in checkpoint blockade and immuno-oncology. His career started with a post-doctoral fellowship at the National Institutes of Health followed by his role as Research Scientist at Aventis Pasteur and then Instructor in Medicine at Harvard Medical School.



**DAN ESTES** (*Partner, Frazier Healthcare Partners*) is a Partner with Frazier Healthcare Partners, a healthcare-focused investment firm

with >\$4B assets under management. He focuses on investments in both development-stage and commercial-stage biopharmaceutical companies. Dan serves on the boards of Sierra Oncology (NASDAQ: SRR), Cirius Therapeutics, Arcutis, Semnur Pharmaceuticals and Outpost Medicine. He has also been involved in Frazier's investments in Acerta (acquired by AstraZeneca), Tobira (acquired by Allergan), Ignyta (acquired by Roche), PreCision Dermatology (acquired by Valeant), and others. Prior to joining Frazier, Dan was a management consultant with McKinsey & Company's healthcare practice, where he led teams that advised global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. He received his Ph.D. in biomedical engineering from the University of Michigan, and also holds a B.S. in electrical engineering from Stanford University.



**JUDY GASSON** (*Senior Advisor, David Geffen School of Medicine Research and Innovation*) has spent more than 30 years at

UCLA in various teaching, research and senior leadership roles. She currently serves as Senior Advisor David Geffen School of Medicine Research and Innovation, a role that she has held since November, 2015 and as a Board member of the UCLA Technology Development Corporation. In this capacity, she works with faculty inventors, business students and faculty, and the Office Technology Development to facilitate the translation of innovative discoveries to address unmet medical needs. She also serves on the Boards of the National Marrow Donor Program, California Institute for Regenerative Medicine, Biocom-LA and the Jonsson Cancer Center Foundation. She served as the Director of UCLA's Jonsson Comprehensive Cancer Center (JCCC) and President of the Jonsson Cancer Center Foundation from September 1995 until September 2015. JCCC is one of only 47 institutions designated as comprehensive cancer centers by the National Cancer Institute, and consistently rated among the nation's top ten institutions, according to U.S. News & World Report. Under her leadership, JCCC became an international pioneer in "translating" laboratory discoveries into more effective new therapies for cancer patients everywhere. Dr. Gasson also served as Senior Associate Dean for Research at the David Geffen School of Medicine from September, 2012 until she retired three years later. She began her career at UCLA in 1983 as a Professor of Medicine (Hematology-Oncology) and Biological Chemistry. Her work was instrumental in purifying for the first time a hormone-like substance that increases the speed of bone marrow cell reproduction. That

substance, called GM-CSF, also had impacts on the granulocytes and monocytes of the immune system. Her academic credentials include a BS degree in Microbiology from Colorado State University and a Doctorate in Physiology from the University of Colorado. She did her post-doctorate work at the Salk Institute in La Jolla, studying glucocorticoid hormones.



**DANIEL GESCHWIND** (*Gordon and Virginia MacDonald Distinguished Chair, Department of Human Genetics; Professor,*

*Departments of Neurology & Psychiatry, UCLA David Geffen School of Medicine*) is the Gordon and Virginia MacDonald Distinguished Professor of Human Genetics, Neurology and Psychiatry at UCLA. In his capacity as Senior Associate Dean and Associate Vice Chancellor of Precision Health, he leads the Institute for Precision Health at UCLA. His laboratory has pioneered the application of systems biology methods in neurologic and psychiatric disease. Dr. Geschwind has put considerable effort into fostering large-scale collaborative patient resources for genetic research and data sharing in autism research. He has published over 400 papers and serves on the editorial boards of *Cell*, *Neuron* and *Science*. He is an elected Member of the American Association of Physicians and the National Academy of Medicine.



**AGI HAMBURGER** (*Senior Director Drug Discovery, A2 Biotherapeutics*) is Senior Director of Drug Discovery at A2

Biotherapeutics, Inc., an early-stage biotechnology company that develops novel medicines for serious illnesses.

Prior to joining A2 in 2018, Agi spent 12 years at Amgen with responsibilities in Biologics - Therapeutic Discovery, contributing to numerous small and large molecule programs in the areas of Oncology, Inflammation, Neuroscience and Cardiometabolic disorders. She was also a project team lead for a portfolio of migraine programs, resulting in three drug candidates currently in clinical development. Agi received her BS in Biochemistry from Purdue University and her PhD in Biology from the Massachusetts Institute of Technology prior to a post-doctoral fellowship at the California Institute of Technology. Her areas of focus were the biochemical and biophysical characterization, including x-ray crystallography, of molecules involved in mucosal immunity as well as viral and bacterial pathogenesis.



**KARIM HELMY** (*Vice President, Venrock*) joined Venrock as a vice president in 2017 and focuses on healthcare with an emphasis on

biotech and medical device. He currently serves on the board of Corvidia Therapeutics. Prior to joining Venrock, Karim was an Engagement Manager in the healthcare practice at McKinsey & Company where he worked with biopharma and device companies of all sizes focusing on clinical, regulatory and BD strategy. Earlier in his career, Karim worked at Genentech where he led a research effort that identified a novel immune receptor and advanced a molecule based on this discovery into pre-clinical development. Karim trained as a physician-scientist, earning MD/PhD degrees from New Jersey Medical School, where he where he graduated with Alpha Omega Alpha honors and received the Stanley S. Bergen, Jr. Medal of Excellence, awarded to the top graduating student in the class. He completed thesis research



as a Howard Hughes Medical Institute Fellow at Memorial Sloan-Kettering Cancer Center studying gene regulation in primary brain tumors. He went on to complete an internship in Internal Medicine at Columbia University Medical Center. Karim received an undergraduate degree in Biological Sciences from Stanford University.



**JOHN HOOD** (*Founder & Chief Executive Officer, Impact Biomedicines*) was the Founder and Chief Executive Officer

of Impact Biomedicines, a company that was acquired by Celgene in 2018 and is now a wholly owned subsidiary of Celgene. Prior to founding Impact, Dr. Hood was the Co-Founder and Chief Scientific Officer of Samumed, a pharmaceutical company focused on advancing regenerative medicine and oncology therapies. Prior to that, Dr. Hood was Director of Research and Co-inventor of fedratinib at TargeGen, Inc., (subsequently acquired by Sanofi SA), where he led a team identifying small molecule kinase inhibitors for the treatment of eye diseases and cancer. He is an inventor on 100+ patents and author on 50+ scientific articles. Dr. Hood obtained a Ph.D. in medical physiology and B.S. in biochemistry from Texas A&M University.



**MICHAEL JUNG** (*Distinguished Professor, Department of Chemistry, UCLA*) received his BA in 1969 from Rice University and his PhD in 1973 from

Columbia University, where he worked with Gilbert Stork as an NSF Fellow. After a one-year NATO postdoctoral fellowship with Albert Eschenmoser at the ETH in Zurich, he joined the faculty at UCLA in 1974, where he is now a Distinguished Professor of Chemistry. He currently consults for 20 industrial laboratories in

both biotech and big pharma settings. He is an authority on synthetic organic and medicinal chemistry and has more than 80 patents and/or applications arising from both his consulting activities and his own research. Recently he has expanded his role in medicinal chemistry at UCLA and has more than 15 ongoing collaborations. Two compounds from his lab have been approved and are on the market: 1) Xtandi, approved 8/31/12 for the treatment of castration-resistant prostate cancer (CRPC), and 2) Erleada, approved 2/14/18 for the treatment of non-metastatic CRPC. He has supervised 92 PhD and 9 Masters theses and has taught 128 postdoctoral scholars. He has published more than 350 articles and given over 625 lectures on his research.



**RAJIV KAUL** (*Portfolio Manager, Fidelity Investments*) is the sector portfolio manager for Fidelity Investments

Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing and other financial products and services to more than 20 million individuals, institutions and financial intermediaries. Mr. Kaul manages Fidelity Select Biotechnology Portfolio and Fidelity Advisor Biotechnology Fund. Mr. Kaul has spent 22 years at Fidelity. During this period, Mr. Kaul has been widely recognized for his leadership within the biotech industry by media outlets such as the Wall Street Journal, New York Times, Bloomberg, CNBC, USA Today, and Barrons to name a few. He is often ranked among the top rated healthcare investors in the US. In 2013, 2014 and 2015 Mr. Kaul was the winner of the Lipper Award for best 3 yr risk-adjusted performance within the Biotechnology and Healthcare industry, adding to this the Best Fund over 5 years Lipper Fund Award for 2015. In April,

2018 Forbes Magazine cited Mr. Kaul as the “best bet” among biotech mutual fund managers based on the ten year performance of the funds he manages. Mr. Kaul is a member of the Research Advisory Council at Massachusetts General Hospital (MGH). MGH is the teaching hospital for Harvard Medical School and is rated the No. 1 hospital in America by US News & World Report. He is a graduate of Harvard University and worked at McKinsey & Company prior to joining Fidelity.



**DUSTIN KHIEM** (*Director, Medical Communications, Kite, A Gilead Company*) has been involved in strategic scientific communications for

close to 10 years, and currently leads Medical Communications at Kite, A Gilead Company. Dustin enjoys synthesizing complex concepts around immuno-oncology into digestible elements to educate the healthcare community. Before joining Kite, Dustin had successfully launched multiple oncology products while at Amgen, where he had either led or executed all aspects of medical affairs. Prior to Amgen, Dustin worked as a consultant with Campbell Alliance and was involved in developing strategic launch plans across commercial and medical affairs organizations. Dustin holds a PhD in Biomedical Sciences from University of California, San Francisco, and a Bachelor of Science degree in Molecular, Cellular, and Developmental Biology from Yale University. You may contact Dustin at [dkhiem@kitepharma.com](mailto:dkhiem@kitepharma.com).



**LUKASZ KOWALIK** (*Business Development Officer, UCLA Technology Development Group*) joined UCLA TDG in August 2017. As a Life

Science Technology Transfer Officer, Lukasz manages the Central Nervous System, Infectious Disease and Stem Cell portfolios. He dedicated his career to enabling innovation in academia and business. His personal innovation philosophy is to create as many productive interfaces as possible between different disciplines, units and industries. Lukasz joined us from Merck KGaA, Darmstadt, Germany, where he was an Innovation Facilitator and Head of the Innovation Think Tank. Prior to that he was a Technology and Business Development Consultant at Now Labs in San Francisco. He holds a BA and MS in Chemistry from Trinity College, University of Cambridge, a PhD in Neuroscience from the Rockefeller University, and he completed his postdoctoral training in Chemical Biology at Stanford University.



**KELSEY C. MARTIN** (*Dean; Professor, Departments of Biological Chemistry & Psychiatry and Biobehavioral Sciences,*

*UCLA David Geffen School of Medicine*) is the Dean of the David Geffen School of Medicine at UCLA. Under her visionary leadership, scientific discoveries are being translated into life-saving cures, health care injustice is being understood and addressed, and the next generation of scientific thought leaders and biotech entrepreneurs is being cultivated. Dr. Martin studied English and American Language and Literature at Harvard University as an undergraduate, went on to serve as a Peace Corps volunteer in the Democratic Republic of Congo where she implemented a life-saving vaccine program, earned her MD-PhD at Yale University and did postdoctoral training with Eric Kandel at Columbia University. She has directed a molecular neurobiology laboratory studying learning and memory at UCLA as a faculty member since 1999.



**JOHN C. MAZZIOTTA** (*Vice Chancellor, UCLA Health Sciences CEO, UCLA Health*) has been Vice Chancellor of UCLA Health Sciences and CEO

of UCLA Health since 2015. A member of the David Geffen School of Medicine faculty since 1983, Dr. Mazziotta also has served as Dean of the medical school, Associate Vice Chancellor of UCLA Health Sciences and Executive Vice Dean. In addition, he was chair of the Department of Neurology and founding director of the Ahmanson-Lovelace Brain Mapping Center. Dr. Mazziotta earned his MD and PhD in neuroanatomy and computer science from Georgetown University. Following an internship at Georgetown, he completed neurology and nuclear medicine training at UCLA. Dr. Mazziotta has published more than 260 research papers and eight texts. He has received numerous awards and honors, including the Oldendorf Award from the American Society of Neuroimaging, the S. Weir Mitchell Award and the Wartenberg Prize of the American Academy of Neurology, and the Von Hevesy Prize from the International Society of Nuclear Medicine. Dr. Mazziotta has been elected to the National Academy of Medicine and the Royal College of Physicians.



**JOHN MILLIGAN** (*President & Chief Executive Officer, Gilead Sciences*) joined Gilead Sciences in 1990 and was appointed

Chief Executive Officer in March 2016. He began his career at Gilead as a research scientist, and subsequently held leadership positions in project management and corporate development before being named Chief Financial Officer in 2002. He was appointed Chief Operating Officer in 2007 and President in 2008. During his tenure at Gilead,

Dr. Milligan has led teams that have developed, manufactured and commercialized more than 20 new therapies for significant unmet needs. He has managed multiple transformative acquisitions, licensing agreements and financings, helping the company grow into a worldwide organization reaching more than 10 million patients. He is a member of the board Pacific Biosciences of California, Inc. and a Trustee of Ohio Wesleyan University. Dr. Milligan received his BA from Ohio Wesleyan University, his PHD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.



**VIJAY MURTHY** (*Principal, JNJ Innovation, JJDC*) is a Principal of Venture Investments at Johnson & Johnson Innovation, JJDC. Inc.

(JJDC) and is based in the Johnson & Johnson Innovation Center in California. Vijay focuses on venture investments in biotechnology, pharmaceuticals, and diagnostics. Prior to joining JJDC, Vijay was a Director of Ventures & Early-Stage Collaborations at AbbVie, where he focused on venture investments and preclinical business development transactions. Prior to AbbVie, Vijay was co-founder and CEO of an early-stage peptide manufacturing company, and an independent consultant to several top-tier life sciences venture capital firms and biopharmaceutical companies. Previously,

Vijay led business development at Enlight Biosciences, a seed-stage venture creation firm founded by PureTech Health and partnered with 7 major biopharmaceutical companies. He started his business career as a strategy consultant at the Boston Consulting Group (BCG). Vijay earned an AM and a PhD in biophysical chemistry from Harvard University, and a BS in chemistry with highest honors and highest distinction from the University of North Carolina at Chapel Hill.



**JANIS NAEVE**  
(Managing Director, Amgen Ventures)

in 2005 and directs the company's corporate venture capital fund focused on early-stage biotechnology companies discovering and developing human therapeutics as well as digital health and healthcare IT. Janis came to Amgen from X-CEPT Therapeutics where she was Director of Corporate Development and supported the acquisition by Exelixis. Prior to this she was Director of Business Development at Aurora Biosciences where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly, and Bristol Myers-Squibb. Janis holds a PhD in pathology from University of Southern California and completed a post-doctoral fellowship at the California Institute of Technology.



**AMIR NAIBERG**  
(Associate Vice Chancellor, UCLA Technology Development Group; President & CEO, UCLA Technology

Development Corporation) leads the UCLA Technology Development Group, a campus wide resource that serves as a Gateway to Innovation, Research and

Entrepreneurship at UCLA. Additionally, he leads the UCLA Technology Development Corporation as Chief Executive Officer and President, a non-profit technology company wholly-owned by UCLA focused on better protecting and optimizing the discoveries and inventions developed through UCLA research. Mr. Naiberg also works in concert with several on campus incubators and accelerators to further advance innovation, entrepreneurship and research at UCLA. Prior to joining UCLA in August 2016, Mr. Naiberg worked at Yeda Research and Development Co, Ltd., in Rehovot, Israel, the technology transfer company of the Weizmann Institute of Science, ranked as one of the top three technology transfer organizations in the world. At Yeda, he served for ten years as CEO, following five years as General Counsel. Mr. Naiberg is one of the founders of the Israel Technology Transfer Organization (ITTN), a non-profit organization that unites various technology transfer offices throughout Israel. Before joining Yeda, he worked for a private law firm specializing in intellectual property, privacy and cyberspace law. Mr. Naiberg holds law degrees from the Hebrew University School of Law and the University of Connecticut School of Law.



**ARIANNE PEREZ GARCIA** (Principal Scientist, Kite, A Gilead Company) was the first scientist to join Kite, A Gilead Company in

February 2014 where she played a key role in the development and characterization of Kite's lead product Yescarta®. She currently leads the T cell biology research team at Kite and is responsible for the pre-clinical characterization of multiple CAR and TCR target molecules for the treatment of hematological and solid tumors. She obtained her PhD in Genetics

and Immunology from University of Barcelona and trained as a postdoc in New York University and Columbia University where she specialized in Cancer Immunology and Immunotherapy.



**DAVID A. PIACQUAD**  
(Senior Vice President, Business Development, Amgen) joined Amgen in 2010 and was named senior vice president,

Business Development, in March 2014. He is responsible for business development across Amgen and leads an organization that combines the previously separate Corporate Development and External Research & Development groups. Prior to this role, Piacquad served as vice president, Strategy & Corporate Development, responsible for mergers and acquisitions, inbound and outbound Licensing, Amgen Ventures and Corporate Alliance Management. Prior to Amgen, Piacquad was senior vice president, Business Development & Licensing at Schering-Plough Corporation. Before joining Schering-Plough, Piacquad spent more than 20 years at Johnson & Johnson, where he held a series of leadership roles in finance and business development. Piacquad holds a BA degree from Colgate University and an MBA from the Wharton School.



**DAVID REESE**  
(Senior Vice President, Translational Sciences & Oncology, Amgen) is responsible for Medical Sciences, Comparative

Biology and Safety Sciences, and Pharmacokinetics and Drug Metabolism. Prior to assuming this role, Reese was vice president of Translational Sciences and therapeutic area head for Oncology Global Development. Reese joined Amgen in 2005 and served in various roles in Global Development and Medical

Sciences. Prior to joining Amgen, Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.



**MARK RIDLEY-THOMAS** (Supervisor, 2nd District, Los Angeles County Board of Supervisors). Since being overwhelmingly elected

in 2008 and reelected in 2012 and 2016 to the Los Angeles County Board of Supervisors, Mark Ridley-Thomas has distinguished himself as an effective leader for more than two million Second District residents. He currently chairs the Board of Supervisors and is a board member of the Los Angeles County Metropolitan Transportation Authority, the Los Angeles Memorial Coliseum Commission, and the nation's largest publicly operated health plan, LA Care. Previously, he represented the 26th District in the California State Senate. He chaired its Committee on Business, Professions and Economic Development, as well as the Legislative Black Caucus in 2008. He led the Caucus in unprecedented levels of collaboration with the Latino and Asian-Pacific Islander Legislative Caucuses. Mark Ridley-Thomas was first elected to public office in 1991 and served with distinction on the Los Angeles City Council for nearly a dozen years, departing as Council

President pro Tempore. He later served two terms in the California State Assembly, where he chaired the Assembly Democratic Caucus. His legislative work addressed a broad range of issues with implications for economic and workforce development, healthcare, public safety, education, budget accountability, consumer protection and civic participation. He also founded the Empowerment Congress, arguably the region's most successful 25-year experiment in neighborhood-based civic engagement. His political career was preceded by his service as executive director of the Southern Christian Leadership Conference of Greater Los Angeles, from 1981 to 1991.



**GUY ROSENTHAL**  
(Business Development Officer, UCLA Technology Development Group)

leads commercial and business development efforts, amongst others, to advance the commercialization of immuno-oncology, immunology, and computational biology programs. Previously, Guy served as the Manager of Academic Affairs and Networks at Teva Pharmaceutical Industries (NASDAQ: TEVA) Global R&D headquarters, where he lead global external innovation with Teva's academic partners. In addition, Guy lead search and evaluation efforts of academic technologies reporting to Teva President of Global R&D and Chief Scientific Officer. Prior to that, Guy served as a Research Associate at VBL Therapeutics (NASDAQ: VBLT), a biotechnology company focused on the discovery, development and commercialization of first in class treatments for immune-inflammatory diseases and cancer. Guy led research in the fields of cancer and cardiovascular diseases, managing the development of novel drug delivery systems. In addition,

Guy is also the Founder and Managing Director of The French Horn Fund, a nonprofit impact fund that invests in social enterprises and special-needs populations in Israel. Guy holds a B.Sc in Biotechnology and a Ph.D in Molecular Biotechnology as part of the Academic-Corporate Partnership Program, Faculty of Life Sciences at Bar Ilan University, Israel.



**ORIAN SHIRIHAI**  
(Professor, Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine)

investigates organellar biology, particularly mitochondria, lysosomes, and autophagosomes. Over the past 15 years, the lab has focused on the study of mitochondrial quality control mechanisms, including fusion, fission, autophagy. The lab is known for developing key imaging approaches to quantify mitochondrial dynamics, motility, mitophagy, and turnover. Using these methodologies to study mitochondrial dynamics, Dr. Shirihai and his team have described the life cycle of the mitochondria and the role of continuous fusion and fission dynamics in the maintenance of bioenergetics capacity and efficiency. The lab played a pivotal role in the creation of leading-edge technology for high throughput respirometry, collaborating on this project with Seahorse Bioscience. Over the year the lab has sustained a variety of active and fruitful collaborations with biotech and pharma companies, partnering on projects involving drug discovery as well as research and medical device development. The lab has trained more than a dozen postdoctoral fellows, four of whom have been recruited as faculty in academic institutions, and two founded new biotech companies.





**BARBARA SOSNOWSKI**  
(Vice President & Global Head, External R&D Innovation, Pfizer) is Vice President and Global Head, External

R&D Innovation Pharmatherapeutics and WRD External Partnerships. As part of the Pharmatherapeutics team, Barbara is the cluster lead for Cardiovascular Metabolic and Inflammation and Immunology Research Units for externally focused efforts. Dr. Sosnowski has more than 30 years in the health care industry. Prior to joining Pfizer 6 years ago, Barbara was Vice President, Biologics Development of Cardium Therapeutics and was appointed Chief Operating Officer of Tissue Repair Company following Cardium's acquisition of Tissue Repair Company in August 2006. Prior to the acquisition, Dr. Sosnowski served as President and CEO of Tissue Repair Company. From June 2001 to December 2004 she served as Vice President Research and Development of Selective Genetics Inc. a tissue repair company that developed wound repair, orthopedic and cardiovascular products. At Selective Genetics, she co-invented and helped develop the targeted gene therapy program, both viral and non-viral. Prior to Selective Genetics she was employed by Prizm Pharmaceuticals from October 1992. Prior to joining Prizm, Dr. Sosnowski was at Ligand Pharmaceuticals, where her efforts were focused on identification of small molecule inhibitors of osteoporosis. Dr. Sosnowski received her BA in Biological Sciences from the University of California, Berkeley and PhD in Biological Sciences from Johns Hopkins University. She is also a registered patent agent.



**MICHAEL TEITELL**  
(Aiya and Harrison Latta Endowed Chair, Department of Pathology; Professor, Departments of Laboratory Medicine &

Pediatrics; Chief, Division of Pediatric and Neonatal Pathology; Director, Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine) is the director of the UCLA Jonsson Comprehensive Cancer Center. He holds the Latta Endowed Chair in Pathology and is a full professor in the Departments of Pathology and Laboratory Medicine, with joint appointments in the Departments of Pediatrics and Bioengineering. He serves as Physician and Chief of the Division of Pediatric and Neonatal Pathology and he has been a member of the cancer center since 1999. Teitell is also a member of the Molecular Biology Institute, the Broad Center of Regenerative Medicine and Stem Cell Research, AIDS Research Institute, and the California NanoSystems Institute at UCLA. Teitell received concurrent bachelor's and master's degrees from the UCLA College Honors Program, and went on to earn combined medical and doctoral degrees at UCLA, where he studied chemistry and biochemistry. He completed his postdoctoral training in anatomic pathology at Brigham and Women's Hospital and Harvard Medical School, and at UC San Francisco as a resident in clinical pathology. Teitell has been elected to the Association of American Physicians and the American Society of Clinical Investigators. Among other recognitions, he received the Stohlman Memorial Scholar Award from the Leukemia Society of America, the Margaret E. Early Medical Research Trust Award and the FOCIS/Millennium Pharmaceuticals Award for Genomics Research.



**JAMES TREANOR**  
(President & Chief Executive Officer, ADRx) is the President and CEO of ADRx Inc., a biotechnology start-up

focused on creating novel therapies for amyloid diseases. Dr. Treanor joined ADRx Inc. in 2014, after a 20 year career in drug discovery and development at Amgen Inc. At Amgen, Dr. Treanor rose to the rank of Scientific Executive Director of Neuroscience research and contributed to the identification and development of numerous therapeutic candidates for Alzheimer's disease, Parkinson's disease, Schizophrenia, Chronic Pain and Migraine. Dr. Treanor conducted his postdoctoral research at Genentech Inc. and his doctorate in the University of Bristol (U.K.) researching treatments for Alzheimer's disease and Parkinson's disease.



**YIBIN WANG**  
(Professor, Department of Anesthesiology and Perioperative Medicine, UCLA David Geffen School of Medicine)

is currently a full Professor of Molecular Medicine in the David Geffen School of Medicine at UCLA. He is the Chair of Cardiovascular Theme at UCLA, the Vice Chair for Research and Director of the Division of Molecular Medicine in the Department of Anesthesiology and Perioperative Medicine. Dr. Wang received his Ph.D. in molecular genetics and cell biology from Baylor College of Medicine and post-doctoral training in neurobiology and molecular cardiology at The Scripps Research Institute and University of California at San Diego. Dr. Wang's research mainly focuses on genetic and molecular mechanisms of heart failure and metabolic disorders. His lab has made major advances in

uncovering stress-signaling mechanisms in the pathogenesis of heart failure, and revealed functional importance amino acids catabolism in heart failure and metabolic disorders. In addition, his lab reported novel regulatory mechanisms in cardiac transcriptome reprogramming involving RNA splicing regulation and non-coding RNA mediated epigenetic modulation. He has served as consultant for several major pharmaceutical companies, including Merck, Pfizer, GSK, Eli Lilly, and Amgen, and biotech start-ups. He holds three patents licensed by different companies.



**MARK WISNIEWSKI**  
(Senior Director, BioPharmaceuticals, UCLA Technology Development Group) joined UCLA TDG in

September 2017 as the Senior Director of BioPharmaceuticals. Prior to joining UCLA TDG, Mark was the Head of Special Projects at Prolacta Bioscience, leading the strategic planning and business development functions. He was also a Principal Advisor to the National Institutes of Health SBIR Commercialization Accelerator Program which provides business strategy, product commercialization, fund raising and strategic partnership guidance to hundreds of biotech and life science companies. Mark was previously at Baxter Healthcare where he held positions in business development, strategic planning, marketing and R&D. Mark received his MBA from the UCLA Anderson School of Management and his Masters of Immunology and Microbiology at the UCLA School of Medicine.



**LAWRENCE ZIPURSKY**  
(Distinguished Professor, Department of Biological Chemistry, UCLA David Geffen School of Medicine) is

a professor of biological chemistry and an investigator of the Howard Hughes Medical Institute at the David Geffen School of Medicine at UCLA. Zipursky was raised in Canada and obtained his BA in Chemistry at Oberlin College. He received his PhD in Molecular Biology at Albert Einstein College of Medicine where he completed his thesis with Dr. Jerard Hurwitz, studying DNA replication in E. coli. In 1981, he moved to the California Institute of Technology to study neural development in Drosophila with Dr. Seymour Benzer as a Helen Hay Whitney Postdoctoral Fellow. He joined the department of biological chemistry at UCLA as a faculty member in 1985 and the Howard Hughes Medical Institute as an investigator in 1991. He is a member of the American Academy of Arts and Sciences and the National Academy of Sciences.



**VICTORIA NIKLAS**  
(Professor, Department of Pediatrics, David Geffen School of Medicine at UCLA; Director, Neonatal

Intensive Care Unit and Newborn Services, Olive View-UCLA Medical Center) earned her Master's Degree in Biochemistry and Molecular Biology from Harvard University and MD from Harvard Medical School. She went on to complete a residency in Pediatrics at the Children's Hospital of Los Angeles and a fellowship in Perinatal and Neonatal Medicine at UCLA. She is currently the Chief Medical and Scientific Officer at Prolacta Bioscience, where she leads the Research and Development team in developing next-generation products from human milk. She also continues to

serve as a Professor of Pediatrics at the UCLA David Geffen School of Medicine and in the practice of neonatology at the Olive View UCLA Medical Center. Victoria is passionate about uncovering therapeutic potentials in human milk and transforming that knowledge into meaningful solutions in health care. Prior to joining Prolacta, she served as the Director of the Neonatal Intensive Care Unit and Newborn Services at Nemours Children's Hospital and subsequently at the Olive View-UCLA Medical Center. Dr. Niklas' research has focused on neonatal gastrointestinal immunology and the role of breast milk in reducing infections and necrotizing enterocolitis in premature newborns. She has also been responsible for groundbreaking research on lactoferrin, a protein found in high abundance in breast milk, in reducing hospital acquired infections in preterm newborns. Dr. Niklas is an experienced neonatologist, educator, mentor and a leader of neonatal intensive care. She is a recognized expert in neonatal intestinal immunology, mouse models of intestinal immune T cell development and in the role of the gut microbiome in the pathogenesis of necrotizing enterocolitis and other diseases that occur throughout life.



# 16

## Pearl Cohen Poster Award Winners for Pioneering Translational Research

**The Pearl Cohen Poster Competition** at the UCLA Biomedical & Life Science Innovation Day is an educational activity for the conference attendees and also provides the benefit of driving engagement between the academic author(s) and pharma/biotech scientific counterparts.

**The Best Poster Award Guidelines are:**

1. Clarity of study goal and hypothesis
2. Clearly outlined scientific and/or health related significance
3. Strength of the research approach
4. Presentation of the data

Overall, the awards will focus on the quality of the science, the presentation format and the capacity of the poster content to concisely convey its significance. First prize is \$750 and second prize is \$250. Two poster winners will be awarded per Research Theme:

- Cancer
- Cardiovascular
- Immunity, Inflammation, Infection, & Transplantation (I3T)
- Metabolism
- Neuroscience
- Precision Medicine
- Regenerative Medicine

### UCLA TECHNOLOGY DEVELOPMENT GROUP (TDG)

## Gateway to Innovation, Research and Entrepreneurship

TDG supports UCLA's research, education and service mission. Working with TDG is a complementary approach to traditional publishing that can facilitate the translation of UCLA discoveries into new products and services that have the potential to broadly benefit the public. Our office manages a large portfolio of technologies and active license agreements, and has a rich history of startup company formation that we continue to build upon.

PATENTS  
•  
LICENSING  
•  
COLLABORATIONS  
•  
STARTUPS  
•  
INVESTMENTS



To learn more about the Technology Development Group, please visit: **TDG.UCLA.EDU** 10889 Wilshire Blvd., Suite 920, Los Angeles, CA 90095 | 310.794.0668 | [info@tdg.ucla.edu](mailto:info@tdg.ucla.edu) | [www.tdg.ucla.edu](http://www.tdg.ucla.edu)



# Sponsors

19

The UCLA Biomedical & Life Science Innovation Day would not be possible if it was not for the generous support of our sponsors and event partners. We are extremely grateful for their help in making the event possible!

Please join us in thanking the following organizations for their contributions and commitment to furthering innovation.

## DIAMOND SPONSORS



**Amgen** is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. On October 3, 2017, Kite became a Gilead company with the completion of the acquisition by Gilead Sciences.

## SILVER SPONSORS

### PEARL COHEN

**Pearl Cohen Zedek Latzer Baratz** ("Pearl Cohen") is an international law firm with offices in the United States, Israel and the United Kingdom. The firm primarily represents innovation-driven enterprises including Fortune 500 and small-cap emerging companies, start-ups and entrepreneurs, investors in the enterprises they form, academic institutions and government-related entities. Contact: Mark Cohen, Senior Partner and Chair of the Life Science Practice Group, mcohen@pearlcohen.com.



**Wilson Sonsini Goodrich & Rosati** is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-

dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm's broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.



**Who is Janssen?** We're more than 30,000 people working hard to prevent, treat, cure and stop some of the most devastating and complex diseases of our time. From heart disease to HIV, Alzheimer's disease to cancer, we are committed to issues that touch everyone's lives. Our mission is to transform individual lives and fundamentally change the way diseases are managed, interpreted, and prevented. We believe that challenging something is the best way to change it. So every day, in more than 150 countries, we bring cutting-edge science and the most creative minds in the industry together to think differently about diseases. We aim not only to innovate but also to empower people with the tools they need to make informed decisions and achieve the best possible results for their health. We are looking at a future where the world of healthcare will be challenged by informed and empowered

patients. We work for change that will improve access to medicines: the best available treatment at an affordable price. That's why we at Janssen strive to provide access to effective and affordable medicines and related healthcare services to the people who need them.



**Xencor** is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 10 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit [xencor.com](http://xencor.com).

## PARTNER SPONSORS



**At Pfizer**, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and

manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

## EVENT PARTNERS



**Biocom** works on behalf of over 1000 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge workforce development and STEM education programs, and create robust value-driven purchasing programs. Biocom provides the strongest public voice for research institutions and life science companies that fuel the California economy.



**The California NanoSystems Institute (CNSI)** at UCLA produces life-changing scientific, economic and social impact in California and across the world. The CNSI environment fosters interdisciplinary teams that collaborate on high-impact research, leveraging the Institute's leading-edge facilities and expert services to address grand challenges of our time. Our team supports innovative startups with progressive training and infrastructure to drive commercialization of research-based technologies. We provide unique educational opportunities for the modern scientific leader by engaging learners from primary school students to established scientists and industry professionals.

## PLATINUM SPONSORS



**Kite** is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. The company has developed



## TRANSFORMING THE LANGUAGE OF LIFE INTO VITAL MEDICINES

At Amgen, we believe that the answers to medicine's most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness — to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, visit [www.amgen.com](http://www.amgen.com)

# Amgen Early Innovator Award Description

**The Amgen Early Innovator Award** supports the translation of promising academic research into technologies that benefit patients. \$75K in funding has been made available to UCLA faculty projects to facilitate this aim. Amgen's generous award contains no commercial obligations.

**This year's recipient** was selected based on a combination of unmet medical need, technical strength and competitive differentiation. Opportunities were evaluated across the UCLA Unified Research Themes:

- Cancer
- Cardiovascular
- Immunity/Inflammation/Infection/Transplantation (I3T)
- Metabolism
- Neuroscience
- Regenerative Medicine





## Victories Over Cancer

Every patient with cancer will face their own unique journey. Along with you, we are committed to helping to redefine that journey. At Janssen Oncology, our dedication lies in developing best-in-class research and solutions to help you and your patients discover everyday moments of victory. Visit [janssen.com/oncology](http://janssen.com/oncology) to learn more.



PHARMACEUTICAL COMPANIES OF 

Janssen Research & Development, LLC JRD © 2018  
The image depicted contains models and is being used for illustrative purposes only.



### Redesigning Antibody Drugs From The Ground Up

**Our employees are the most important factor in our success.**  
*We have assembled a highly talented group from diverse backgrounds and disciplines to execute our business plan and shape our future. Xencor employees value new ideas and flexibility and demand from each other scientific rigor, a passion for innovation, and a willingness to take risks.*



Xencor Inc. is an innovative biotechnology company located in the Los Angeles area (near Pasadena) and in San Diego. We use our pioneering XmAb® technology to develop better biotherapeutics to improve patient outcomes and quality of life.

[www.xencor.com](http://www.xencor.com)



Strategic **PARTNERSHIP** is at the heart of fulfilling Pfizer’s purpose as we work to translate advanced science and technologies into medicines and vaccines that significantly improve patients’ lives.

[www.pfizer.com/partners/research-and-development](http://www.pfizer.com/partners/research-and-development)

Visit the Pfizer partnering website to learn more about:

- Our Areas of Interest
- Our Partnering Leadership
- Our Process
- Contact Information
- Partnering Highlights





YAY  
HOORAY!  
..... **UCLA TDG’S** .....  
NEW SITE  
*is on it’s way!*

**LAUNCHING LATE JUNE 2018**



# INNOVATION MATTERS

A unique perspective on a changing landscape


Faced with uncertain economic times and a volatile global marketplace, you need a law firm with the experience, skills, and resources to help you navigate shifting terrain. For more than 50 years, Wilson Sonsini Goodrich & Rosati has owed its success to being as innovative and cutting edge as the technology, life sciences, and growth enterprises that we represent. Let us show you why innovation matters in a law firm—and why you matter to us.

For more information, please visit [wsgr.com](http://wsgr.com)



**Wilson Sonsini Goodrich & Rosati**  
PROFESSIONAL CORPORATION

NEW YORK BOSTON TEL AVIV LOS ANGELES LONDON



### Life Science Practice

Our Life Sciences Practice Group represents biotechnological, chemical, pharmaceutical, nanotechnology, and medical technologies. At Pearl Cohen Zedek Latzer Baratz LLP, the convergence of science, technology, law and business is at your service.

Mark Cohen  
Senior Partner  
Chair of Life Sciences Practice Group  
[MCohen@PearlCohen.com](mailto:MCohen@PearlCohen.com)

**PEARL COHEN**

Pearl Cohen Zedek Latzer Baratz LLP



A GILEAD Company

*Focused on the cure*

Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do from early research to product development.

# Change the world with us

[kitepharma.com/careers](http://kitepharma.com/careers)



© 2018 Regents of the University of California

10889 Wilshire Blvd., Suite 920, Los Angeles, CA 90095  
310.794.0668 | [info@tdg.ucla.edu](mailto:info@tdg.ucla.edu) | [www.tdg.ucla.edu](http://www.tdg.ucla.edu)

